Healthcare
Quote through 2026-08-05T13:30:00Z · Stale
Quote synced 2026-08-05T23:25:48.499015Z
Daily bars through 2026-08-03 · Stale
Daily bars synced 2026-08-04T15:35:19.331132Z
Fundamentals through 2026-05-04 · Current
Fundamentals synced 2026-08-05T22:39:51.787625Z
Forecasts: Stale
Forecasts synced 2026-05-05T11:57:48.711655Z
Ownership: Missing
Ownership synced 2026-08-05T22:39:51.787625Z
Short interest: Missing
Short interest synced 2026-08-05T22:39:51.787625Z
News through 2026-05-21T02:30:00Z · Stale
News synced 2026-05-21T08:13:40.628796Z
Company profile: Delayed
Company profile synced 2026-05-06T21:57:49.68488Z
Regular-session price
Offline$105.71
+0.24% regular session
1Y Change
-19.06%
Window
Aug 5, 2025 → Aug 4, 2026
Investment Snapshot
Valuation, growth, profitability, catalysts, and benchmark context.
1D
+0.2%
1M
+10.6%
6M
-2.2%
YTD
-14.8%
1Y
-19.1%
Coverage: 250 bars · Aug 5, 2025 → Aug 4, 2026
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
ABT is 41.89 pts behind over the shared 1Y window.
ABT had 30.44 pts deeper max drawdown than SPY.
ABT beat SPY in 0 of 2 calendar years shown and trailed in 2.
ABT
-19.06%
Normalized return
SPY
+22.83%
S&P 500
Excess Return
-41.89 pts
Relative to SPY
ABT Max Drawdown
-39.57%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Uses the longest available daily history for ABT and SPY.
| Year | ABT | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | -14.82% | +12.67% | -27.50 pts | SPY |
| 2025 | -3.76% | +9.40% | -13.16 pts | SPY |
Financials
Annual, quarterly, and TTM views with reported currency, units, source, download, and filing context.
Period
Units
Reported currency
USD
Source
FMP
Last checked
Apr 7, 2026
FY Revenue
$44.3B
+5.7% YoY
FY Net Income
$6.5B
-51.3% YoY
Free Cash Flow
$7.4B
+16.4% YoY
Revenue Growth
+5.7%
EPS Growth
-51.2%
Gross Margin
56.4%
Net Margin
13.9%
Income statement
USD
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 43,075M | 43,653M | 40,109M | 41,950M | 44,328M |
| Gross Profit | 23,214M | 22,323M | 20,037M | 21,325M | 24,607M |
| Operating Income | 9,200M | 8,362M | 6,435M | 6,825M | 8,048M |
| EBITDA | 12,159M | 11,888M | 10,605M | 10,834M | 11,553M |
| Net Income | 7,071M | 6,933M | 5,723M | 13,402M | 6,524M |
| EPS (Diluted) | -- | -- | -- | -- | -- |
Balance sheet
USD
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 9,799M | 9,882M | 6,896M | 7,616M | 8,522M |
| Total Assets | 75,196M | 74,438M | 73,214M | 81,414M | 86,713M |
| Total Liabilities | 39,172M | 37,533M | 34,387M | 33,513M | 33,942M |
| Shareholder Equity | 35,802M | 36,686M | 38,603M | 47,664M | 52,130M |
| Total Debt | 19,251M | 17,946M | 15,873M | 15,275M | 15,067M |
| Net Debt | 9,452M | 8,064M | 8,977M | 7,659M | 6,545M |
Cash flow positioning
2025
Operating Cash Flow
9,566M
+11.8% YoY
Capital Expenditures
2,171M
+1.6% YoY
Free Cash Flow
7,395M
+16.4% YoY
Key ratios
Gross Margin
56.4%
Operating Margin
18.2%
Net Margin
13.9%
ROE
12.2%
Debt / Equity
0.65x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.